⁶⁸Ga-PSMA PET/CT scanning has been shown to be more sensitive than conventional imaging techniques in patients with prostate cancer. This prospective Australian multicenter study assessed whether ⁶⁸Ga-PSMA PET/CT imaging affects management intent in patients with primary or recurrent prostate cancer. Methods: Before undertaking ⁶⁸Ga-PSMA PET imaging, referring medical specialists completed a questionnaire detailing relevant demographic and clinical data as well as their proposed management plan. A separate follow-up questionnaire was completed after the ⁶⁸Ga-PSMA PET/CT scan results were available to determine whether the management plan would change. Results: A total of 431 patients with prostate cancer from 4 Australian centers had pre– and post–⁶⁸Ga-PSMA management plans completed. Scans were obtained for primary staging of intermediate- and high-risk disease in 25% of patients and for restaging/biochemical recurrence in 75% of patients. Overall, ⁶⁸Ga-PSMA PET/CT scanning led to a change in planned management in 51% of patients. The impact was greater in the group of patients with biochemical failure after definitive surgery or radiation treatment (62% change in management intent) than in patients undergoing primary staging (21% change). Imaging with ⁶⁸Ga-PSMA PET/CT revealed unsuspected disease in the prostate bed in 27% of patients, locoregional lymph nodes in 39%, and distant metastatic disease in 16%. Conclusion: ⁶⁸Ga-PSMA PET/CT scans detect previously unsuspected disease and may influence planned clinical management in a high proportion of patients with prostate cancer. The impact was greater in patients with biochemical recurrence. These results demonstrate the potential clinical value of ⁶⁸Ga-PSMA PET/CT in management of prostate cancer.

⁶⁸ Ga-PSMA PET / CT扫描对前列腺癌患者比常规成像技术更为敏感。这项前瞻性的澳大利亚多中心研究评估了⁶⁸ Ga-PSMA PET / CT成像是否会影响原发性或复发性前列腺癌患者的治疗意图。方法：在进行⁶⁸ Ga-PSMA PET成像之前，转诊的医学专家完成了一份问卷，其中详细列出了相关的人口统计和临床数据以及他们提出的管理计划。在获得⁶⁸ Ga-PSMA PET / CT扫描结果以确定管理计划是否会改变之后，完成了另一份后续调查表。结果：来自澳大利亚4个中心的431名前列腺癌患者已完成^68项Ga-PSMA管理计划的前后。在25％的患者中进行了中，高危疾病的初级分期，在75％的患者中进行了分期/生化复发的扫描。总体而言，对^68％的Ga-PSMA PET / CT扫描导致51％的患者计划管理发生了变化。最终手术或放疗后发生生化衰竭的患者组的影响更大（管理意图改变了62％），而经历了初次分期的患者（影响改变了21％）更大。用⁶⁸ Ga-PSMA PET / CT进行的成像显示，27％的患者前列腺床上未发现疾病，39％的局部淋巴结转移，16％的远处转移性疾病。结论： ^68次Ga-PSMA PET / CT扫描可检测到以前未曾怀疑的疾病，并且可能会影响到很大比例的前列腺癌患者的计划临床治疗。生化复发患者的影响更大。这些结果证明了⁶⁸ Ga-PSMA PET / CT在治疗前列腺癌中的潜在临床价值。